Cochrane Evidence Synthesis and Methods ►

Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To determine the benefits and harms of dose reduction or discontinuation of biological or targeted synthetic disease-modifying anti-rheumatic drugs in adults with axial spondyloarthritis and low disease activity or remission.

This is a protocol.

Published:

22 November 2021

Authors:

Avery JC, Whittle SL, Johnston RV, Grobler L, McKenzie BJ, Cyril S, van der Heijde D, Buchbinder R

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Avery JC, Whittle SL, Johnston RV, Grobler L, McKenzie BJ, Cyril S, van der Heijde D, Buchbinder R. Dose reduction and discontinuation of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity (Protocol). Cochrane Database of Systematic Reviews 2021, Issue 11. Art. No.: CD014836. DOI: 10.1002/14651858.CD014836.